Premium
Genetic variations in human papillomavirus and cervical cancer outcomes
Author(s) -
Rader Janet S.,
Tsaih ShirngWern,
Fullin Daniel,
Murray Miriam W.,
Iden Marissa,
Zimmermann Michael T.,
Flister Michael J.
Publication year - 2019
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32038
Subject(s) - locus (genetics) , cervical cancer , human papillomavirus , lineage (genetic) , biology , virus , clade , gene , medicine , virology , oncology , cancer , genetics , phylogenetics
Cervical cancer is driven by persistent infection of human papillomavirus (HPV), which is influenced by HPV type and intratypic variants, yet the impact of HPV type and intratypic variants on patient outcomes is far less understood. Here, we examined the association of cervical cancer stage and survival with HPV type, clade, lineage, and intratypic variants within the HPV E6 locus. Of 1,028 HPV‐positive cases recruited through the CerGE study, 301 were in‐situ and 727 were invasive cervical cancer (ICC), with an average post‐diagnosis follow‐up of 4.8 years. HPV sequencing was performed using tumor‐isolated DNA to assign HPV type, HPV 16 lineage, clade, and intratypic variants within the HPV 16 E6 locus, of which nonsynonomous variants were functionally annotated by molecular modeling. HPV 18‐related types were more prevalent in ICC compared to in‐situ disease and associated with significantly worse recurrence‐free survival (RFS) compared to HPV 16‐related types. The HPV 16 Asian American lineage D3 and Asian lineage A4 associated more frequently with ICC than with in situ disease and women with an intratypic HPV 16 lineage B exhibited a trend toward worse RFS than those with A, C, or D lineages. Participants with intratypic E6 variants predicted to stabilize the E6–E6AP–p53 complex had worse RFS. Variants within the highly immunogenic HPV 16 E6 region (E14–I34) were enriched in ICC compared to in‐situ lesions but were not associated with survival. Collectively, our results suggest that cervical cancer outcome is associated with HPV variants that affect virus‐host interactions.